TAM Receptor Tyro3, Axl and Mertk receptors

Cat.No.	Name	Information
M8915	Dubermatinib	Dubermatinib (TP-0903) is a potent and selective AXL inhibitor with an IC50 value of 27 nM.
M2023	Bemcentinib	Bemcentinib (R428) is a potent and selective small-molecule inhibitor of Axl kinase with IC50 of 14 nM.
M21696	Batiraxcept	Batiraxcept (AVB-S6-500) is a highly potent and specific GAS6-AXL signaling pathway inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro.
M11240	Zanzalintinib	Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity.
M11238	UNC569	UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with IC50 of 2.9 nM and Ki of 4.3 nM. UNC569 also inhibited Axl and Tyro3 with IC50 of 37 nM and 48 nM, respectively.
M11231	LDC1267	LDC1267 is a highly selective inhibitor of TAM (Tyro3,Axl and Mer) kinases with IC50 values of <5 nM/8 nM/29 nM against Tyro3/Axl/Mer, respectively.
M10497	ONO-7475	ONO-7475 is a potent and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively.
M9385	RU-301	RU-301 is a pan-TAM receptor inhibitor that blocks Gas6-induced TAM activation and tumorigenicity, with Kd and IC50 values of 12 μM and 10 μM, respectively.
M4875	UNC2881	UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively
M3108	UNC2250	UNC2250 is a potent and selective Mer inhibitor with IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.
M2180	SGI-7079	SGI-7079 is a novel Axl inhibitor.
M57220	UNC1062	UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells.
M57219	AZ14145845	AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
M43535	Axl/Mer/CSF1R-IN-2	Axl/Mer/CSF1R-IN-2 is a Axl, Mer and CSF1R inhibitor.
M43534	AXL-IN-15	AXL-IN-15 is a potent Axl inhibitor with both Ki and IC50 <1 nM.
M30936	Glesatinib	Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).
M28955	DS-1205b free base	DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.
M28324	Ningetinib Tosylate	Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
M27894	RU-302	RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC50in cell assays, and suppresses lung cancer tumor growth.
M25072	Mipasetamab uzoptirine	Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers.

By Signaling Pathways

By Product Type

Signaling Pathways

TAM Receptor Tyro3, Axl and Mertk receptors

Get to Know Us

Customer Support

Resources

Contact Us